Blended solutions gain momentum and reveal untapped potential
Promised land
Related Posts
Owlstone Medical announces $27 million USD first close in Series E financing round
Funds to accelerate commercialisation and clinical trials of diagnostic tests Owlstone Medical has announced a first close of $27 million (circa £22 million) in its […]
Argenx receives positive CHMP opinion for CIDP treatment
VYVGART could be the first CIDP drug with a novel mechanism in 30 years Argenx has announced that the Committee for Medicinal Products for Human […]
4TEEN4 begins trial of antibody therapy for cardiogenic shock
First patient dosed in phase 1b/2a study of procizumab 4TEEN4 Pharmaceuticals has dosed the first patient in a phase 1b/2a trial of procizumab, a monoclonal […]